Primary outcome
What NCT02299388 measured first
| Liraglutiden=6 | Placebon=2 |
|---|---|
| -4.88(-18.6 to 13.6) | -5.45(-6.9 to -4.0) |
From the results posted on ClinicalTrials.gov (NCT02299388), updated at source Jan 27, 2021.
Phase 4 · Liraglutide
NCT02299388 trial results
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors. (mm/Hg), Baseline and 8 Weeks. Liraglutide: -4.88; Placebo: -5.45.
- Participants
- 11
- Status
- completed
- Completed
- 2016-12
- Sponsor
- Tulane University School of Medicine
As posted on ClinicalTrials.gov (NCT02299388), updated at source Jan 27, 2021. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Secondary outcomes
What else it measured
| Measure | Liraglutiden=6 | Placebon=2 |
|---|---|---|
| Overall Systolic Pressure | -4.4(-18.5 to 11.8) | -5.4(-9.4 to -1.4) |
| Overall Diastolic Pressure | -1.8(-7.5 to 9.5) | -3.3(-9.8 to 3.2) |
| Overall Pulse Pressure | -2.7(-11 to 1.4) | 0.4(0.4 to 0.4) |
| Mean Arterial Pressure | -2.6(-11.2 to 10.3) | -4(-9.7 to 1.7) |
| Nocturnal Systolic Pressure | 1.15(-18.5 to 14.7) | -2.3(-25.3 to 20.6) |
| Nocturnal Diastolic Pressure | 1.0(-12.1 to 19) | -0.8(-14 to 12.5) |
From the results posted on ClinicalTrials.gov (NCT02299388), updated at source Jan 27, 2021.
The trial
How NCT02299388 was run
The investigators are conducting this research to study the effect of Liraglutide on blood pressure. Several studies have shown increased cardiovascular complications and deaths in diabetics with hypertension. The importance of blood pressure control in diabetes has been shown in many clinical trials. No drug already approved for treating Type 2 Diabetes Mellitus is known to reduce blood pressure along with improving diabetes. However, prior research studies with liraglutide have suggested that treatment with liraglutide improves blood pressure. This effect is seen very quickly and even prior to any weight loss. The mechanism behind this effect is yet to be determined.
- Liraglutide: All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
- Placebo: All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
Who could join the trial
Inclusion Criteria: * Type 2 diabetes, as an adjunct to diet and exercise to improve glycemic control (as per approved label. * HbA1c\>7% and ≤10.5% at randomization. * Men and women of 18-75 years of age. * Women of childbearing potential must agree to use contraception or must not otherwise be at risk of becoming pregnant. A urine pregnancy test will be done at the time of screening and then every 4 weeks for the duration of 8 weeks. If positive, this will be confirmed with a serum pregnancy test which if positive, appropriate action will be taken as outlined in the detailed protocol. * Blood pressure≥ 130/80 mm Hg and ≤160/100mmHg on stable treatment (no change in anti hypertensive treatment for 3 months prior to screening) or no treatment. No change in treatment for BP over 8 weeks of the study will be allowed. * Patient understands the study procedures, alternative treatments are available, and the risks involved with the study, and voluntarily agree to participate by providing written informed consent. Exclusion Criteria: * 1\. Type 1 diabetes and/or history of ketoacidosis determined by medical history. 2\. History of severe diabetic or autonomic neuropathy, gastroparesis or limb ulceration or amputation. 3\. Therapy with DPP-4 inhibitor, or GLP -1 analog or receptor agonist in the past 6 months. 4\. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures. 5\. Patients on corticosteroids within 3 months or recurrent continuous corticosteroid treatment (\>2 weeks). 6\. Use of weight loss drugs within 3 months of screening or weight loss of ≥10 % in the last 6 months. 7\. Surgery in the past 30 days prior to screening and/or any serious or chronic illness within 6 months or anticipated surgery during the trial period. 8\. Serum creatinine \>1.4mg/dL (women)/\>1.5mg/dL (men). 9. Serum Triglyceride Level \>500 mg/dL. 10. History of pancreatitis. 11. History of drug or alcohol abuse. 12. Poor mental function or any reason to expect patient difficulty in complying with study requirements. 13\. Contraindications to Liraglutide: Personal or family history of medullary thyroid cancer or MEN-2 syndrome 14. Known or suspected allergy to Liraglutide. 15. Diagnosed Secondary hypertension.
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.